Rao, A., Khan, G., Rizzieri, D. A., Moore, J. O., Gockerman, J. P., Diehl, L. F., … Decastro, C. (2012). Phase 1 Study of Lenalidomide and Decitabine for High and Intermediate 2 Risk MDS. In Blood (Vol. 120, pp. 4935–4935). American Society of Hematology. https://doi.org/10.1182/blood.v120.21.4935.4935

Rao, Arati, Ghazi Khan, David A. Rizzieri, Joseph O. Moore, Jon P. Gockerman, Louis F. Diehl, Anne W. Beaven, Donna Adams, Julie Warzecho, and Carlos Decastro. “Phase 1 Study of Lenalidomide and Decitabine for High and Intermediate 2 Risk MDS.” In Blood, 120:4935–4935. American Society of Hematology, 2012. https://doi.org/10.1182/blood.v120.21.4935.4935.

Rao A, Khan G, Rizzieri DA, Moore JO, Gockerman JP, Diehl LF, et al. Phase 1 Study of Lenalidomide and Decitabine for High and Intermediate 2 Risk MDS. In: Blood. American Society of Hematology; 2012. p. 4935–4935.

Rao, Arati, et al. “Phase 1 Study of Lenalidomide and Decitabine for High and Intermediate 2 Risk MDS.” Blood, vol. 120, no. 21, American Society of Hematology, 2012, pp. 4935–4935. Crossref, doi:10.1182/blood.v120.21.4935.4935.

Rao A, Khan G, Rizzieri DA, Moore JO, Gockerman JP, Diehl LF, Beaven AW, Adams D, Warzecho J, Decastro C. Phase 1 Study of Lenalidomide and Decitabine for High and Intermediate 2 Risk MDS. Blood. American Society of Hematology; 2012. p. 4935–4935.